Other research analysts have also issued reports about the company. JMP Securities reiterated a “market outperform” rating and set a $22.00 price target on shares of Kura Oncology in a report on Thursday, September 5th. BidaskClub upgraded Kura Oncology from a “strong sell” rating to a “sell” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Kura Oncology in a report on Friday, August 2nd. Wedbush reiterated a “positive” rating on shares of Kura Oncology in a report on Wednesday, September 4th. Finally, Deutsche Bank assumed coverage on Kura Oncology in a report on Thursday, July 18th. They set a “buy” rating and a $28.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. Kura Oncology has a consensus rating of “Buy” and an average target price of $27.10.
Shares of KURA stock traded up $0.51 during trading hours on Monday, reaching $14.97. 153,846 shares of the company’s stock were exchanged, compared to its average volume of 264,000. Kura Oncology has a fifty-two week low of $10.20 and a fifty-two week high of $21.42. The stock has a market capitalization of $676.41 million, a P/E ratio of -8.70 and a beta of 2.58. The business has a fifty day moving average price of $15.19 and a 200-day moving average price of $16.94. The company has a quick ratio of 23.50, a current ratio of 23.50 and a debt-to-equity ratio of 0.03.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. As a group, research analysts expect that Kura Oncology will post -1.61 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in KURA. Marshall Wace LLP bought a new stake in shares of Kura Oncology during the first quarter valued at approximately $372,000. SG Americas Securities LLC bought a new stake in shares of Kura Oncology during the second quarter valued at approximately $137,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Kura Oncology by 599.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after purchasing an additional 2,420 shares during the period. DekaBank Deutsche Girozentrale increased its position in shares of Kura Oncology by 63.3% during the second quarter. DekaBank Deutsche Girozentrale now owns 19,600 shares of the company’s stock valued at $388,000 after purchasing an additional 7,600 shares during the period. Finally, Swiss National Bank increased its position in shares of Kura Oncology by 36.1% during the second quarter. Swiss National Bank now owns 61,400 shares of the company’s stock valued at $1,209,000 after purchasing an additional 16,300 shares during the period. Institutional investors and hedge funds own 85.46% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Further Reading: Lock-Up Period Expiration
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.